CF PharmTech Buys Back 49,500 H-Shares, Raising Treasury Stock to 0.30% of Mandate Limit

Bulletin Express05-21 19:23

CF PharmTech, Inc. disclosed that it repurchased 49,500 H-shares on 21 May 2026 through on-exchange transactions. The buyback was executed within a price range of HKD 18.94–20.46 per share, with a volume-weighted average cost of HKD 19.48 per share and a total outlay of HKD 0.96 million.

Following the transaction: • Issued shares (excluding treasury shares) declined by 0.0164% to 301.32 million. • Treasury shares increased to 901,000, lifting the company’s total share count—including treasury stock—to 302.22 million. • All repurchased shares are being held in treasury; none have been cancelled.

The board’s repurchase mandate, approved on 16 December 2025, authorises the company to buy back up to 30.22 million shares. Cumulative repurchases under this mandate now stand at 901,000 shares, representing 0.30% of the authorised limit and 0.2981% of the issued share base at the mandate date.

In accordance with Hong Kong Stock Exchange rules, CF PharmTech is restricted from issuing, selling, or transferring any shares until 20 June 2026, 30 days after the latest repurchase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165777067?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 19:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165777067","market":"hk","top_or_hot":-1,"title":"CF PharmTech Buys Back 49,500 H-Shares, Raising Treasury Stock to 0.30% of Mandate Limit","media":"Bulletin Express","content":"<p>CF PharmTech, Inc. disclosed that it repurchased 49,500 H-shares on 21 May 2026 through on-exchange transactions. The buyback was executed within a price range of HKD 18.94–20.46 per share, with a volume-weighted average cost of HKD 19.48 per share and a total outlay of HKD 0.96 million.</p>\n<p>Following the transaction:\n• Issued shares (excluding treasury shares) declined by 0.0164% to 301.32 million.  \n• Treasury shares increased to 901,000, lifting the company’s total share count—including treasury stock—to 302.22 million.  \n• All repurchased shares are being held in treasury; none have been cancelled.</p>\n<p>The board’s repurchase mandate, approved on 16 December 2025, authorises the company to buy back up to 30.22 million shares. Cumulative repurchases under this mandate now stand at 901,000 shares, representing 0.30% of the authorised limit and 0.2981% of the issued share base at the mandate date.</p>\n<p>In accordance with Hong Kong Stock Exchange rules, CF PharmTech is restricted from issuing, selling, or transferring any shares until 20 June 2026, 30 days after the latest repurchase.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PharmTech Buys Back 49,500 H-Shares, Raising Treasury Stock to 0.30% of Mandate Limit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PharmTech Buys Back 49,500 H-Shares, Raising Treasury Stock to 0.30% of Mandate Limit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-21 19:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CF PharmTech, Inc. disclosed that it repurchased 49,500 H-shares on 21 May 2026 through on-exchange transactions. The buyback was executed within a price range of HKD 18.94–20.46 per share, with a volume-weighted average cost of HKD 19.48 per share and a total outlay of HKD 0.96 million.</p>\n<p>Following the transaction:\n• Issued shares (excluding treasury shares) declined by 0.0164% to 301.32 million.  \n• Treasury shares increased to 901,000, lifting the company’s total share count—including treasury stock—to 302.22 million.  \n• All repurchased shares are being held in treasury; none have been cancelled.</p>\n<p>The board’s repurchase mandate, approved on 16 December 2025, authorises the company to buy back up to 30.22 million shares. Cumulative repurchases under this mandate now stand at 901,000 shares, representing 0.30% of the authorised limit and 0.2981% of the issued share base at the mandate date.</p>\n<p>In accordance with Hong Kong Stock Exchange rules, CF PharmTech is restricted from issuing, selling, or transferring any shares until 20 June 2026, 30 days after the latest repurchase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"","article_id":"1165777067","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165777067","pubTimestamp":1779362628,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CF PharmTech, Inc. disclosed that it repurchased 49,500 H-shares on 21 May 2026 through on-exchange transactions. The buyback was executed within a price range of HKD 18.94–20.46 per share, with a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02652":"长风药业"},"translate_title":"CF PharmTech回购49,500股H股，将库存股提高至授权限额的0.30%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1},"content_text":"CF PharmTech, Inc. disclosed that it repurchased 49,500 H-shares on 21 May 2026 through on-exchange transactions. The buyback was executed within a price range of HKD 18.94–20.46 per share, with a volume-weighted average cost of HKD 19.48 per share and a total outlay of HKD 0.96 million.\nFollowing the transaction:\n• Issued shares (excluding treasury shares) declined by 0.0164% to 301.32 million.  \n• Treasury shares increased to 901,000, lifting the company’s total share count—including treasury stock—to 302.22 million.  \n• All repurchased shares are being held in treasury; none have been cancelled.\nThe board’s repurchase mandate, approved on 16 December 2025, authorises the company to buy back up to 30.22 million shares. Cumulative repurchases under this mandate now stand at 901,000 shares, representing 0.30% of the authorised limit and 0.2981% of the issued share base at the mandate date.\nIn accordance with Hong Kong Stock Exchange rules, CF PharmTech is restricted from issuing, selling, or transferring any shares until 20 June 2026, 30 days after the latest repurchase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165777067","isCrawlerRequest":true}